Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2022-08-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力独立董事关于第八届董事会第14次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 14th meeting of the 8th board of directors of a company. It addresses approval of a related-party transaction and the termination of a subsidiary's planned spin-off listing on the Shanghai Stock Exchange's STAR Market. The content focuses on board meeting decisions and compliance with laws and company articles, rather than financial results or detailed financial data. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting result announcement. The document is a formal board/management related announcement concerning board meeting matters and opinions from independent directors. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and contains substantive content related to board decisions, not just an announcement of a report publication or certification, so it is not RPA or RNS. Confidence is high due to clear identification of board meeting and independent director opinions on corporate governance matters.
2022-08-19 Chinese
天士力关于终止分拆所属子公司上市的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the company TianShiLi Pharmaceutical Group Co., Ltd. regarding the termination of the spin-off and listing of its subsidiary TianShiLi Biopharmaceutical Co., Ltd. on the Shanghai Stock Exchange's Science and Technology Innovation Board. It details the history of the spin-off plan, the decision to terminate it, reasons for termination, and the impact on the company. The document is a formal announcement about a corporate action (termination of a planned subsidiary listing) rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but is a corporate event announcement. This fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure plans and financing activities (termination of a planned subsidiary IPO). The document length is short (1951 characters), but it is not merely announcing the publication of a report; it is the announcement itself. Therefore, the appropriate classification is CAP with high confidence.
2022-08-19 Chinese
天士力关于修订公司章程部分条款的公告
Governance Information Classification · 95% confidence The document is an announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding amendments to its Articles of Association (公司章程). It details specific changes to the company's registered capital, business scope, governance provisions, and other internal rules. The document includes references to board resolutions and the need for shareholder approval at a general meeting. It is a formal disclosure of corporate governance changes and internal rules rather than a full report or financial statement. There is no indication that this is a full Annual Report, Interim Report, or any financial statement. It is not a voting result announcement or a proxy solicitation. The document is a regulatory announcement about governance and corporate charter amendments, fitting best under Governance Information (CGR). The document length is substantial and contains detailed governance content, supporting a high confidence classification as CGR.
2022-08-19 Chinese
辽宁天士力参茸保健品有限公司因资产转让事宜的资产评估报告
Audit Report / Information Classification · 95% confidence The document is an asset valuation report prepared by Shanghai Lixin Asset Appraisal Co., Ltd. for Liaoning Tianshili Ginseng Health Products Co., Ltd. It details the market value assessment of certain industrial real estate and internal non-removable equipment as of December 31, 2021, for the purpose of asset transfer. The report includes detailed valuation methods, legal and regulatory references, asset descriptions, and conclusions. It is a comprehensive standalone asset appraisal report, not an announcement or summary of another report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Audit Report / Information (AR), which includes standalone audit or valuation reports and applied accounting principles. Therefore, the document should be classified as AR with high confidence.
2022-08-19 Chinese
天士力第八届董事会第14次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from TianShiLi Pharmaceutical Group Co., Ltd. It details the resolutions passed at the 14th meeting of the 8th board, including approval of the 2022 semi-annual report, amendments to the company articles, asset purchase by a subsidiary, termination of a subsidiary's listing plan, and notice of a shareholders meeting. The document references other announcements and reports published on the Shanghai Stock Exchange website but does not contain the full semi-annual report or detailed financial data itself. It is primarily a board/management information announcement about decisions made at a board meeting, not the report itself or a voting result announcement. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short (1299 characters), consistent with an announcement rather than a full report.
2022-08-19 Chinese
天士力2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company information, risk disclosures, and operational details for the first half of 2022. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial analysis. The content matches the characteristics of an Interim / Quarterly Report (IR) rather than a brief announcement or a full annual report (10-K). The document is not a certification, announcement, or presentation but a comprehensive financial report for a period shorter than a full fiscal year. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2022-08-19 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.